Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3745)	10/6/1999 6:44:00 PM
From: PaulW	Read Replies (1) \| Respond to of 10280

Peter - I posted my response to show what can happen during an FTC investigation - namely business as usual with the FDA for SEPR as a direct response to Mazen's question. Relative to SEPR and LLY, we both agree that it is a silly investigation. But, rumors can get created that can negatively impact the price of a stock - hopefully there will be no false negative rumors pertaining to SEPR. I suggest that you read what is going on with ADRX over the last few days, and how the company is handling it - because the possibility exists that someone might spread rumors about SEPR and you might benefit by having the knowledge by observing the price action and history of another stock that made the national press going through an investigation. Also, you wrote " The ADRX/HOE deal is pretty uncompetitive on its face - basically HOE is paying ADRX handsomely to keep the generic off the market. (It's obviously more complicated than that because of the patent dispute, but that's still what a surface reading gives you). " Obviously, I disagree with you (I am not a lawyer). But, if that is what potential investors think the agreement looks like and shy away from ADRX or sold ADRX because of this, who is to say investors will not come away with some dumb interpretation of the LLY/SEPR agreement.